In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celesio AG

www.celesio.com

Latest From Celesio AG

European Notebook: EMA Meetings Go (Somewhat) Public; Walgreens’ Global Reach; Scottish Independence?

The European Medicines Agency moves closer to U.S.-style advisory committee meetings in public; two national referendums next month could hit Scotland’s biotech industry and Switzerland’s health insurance sector.

BioPharmaceutical Europe

Actavis’ Big Bet On A Diversified Hybrid Model

Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.

BioPharmaceutical Strategy

European Notebook: Price Freezes, European Elections To Feature In 2014

This month’s European Notebook scans the horizon for European legislative and regulatory changes affecting the pharmaceutical industry in the next 12 months, including drug price freezes in Germany and the U.K., the heated debate over clinical trial data transparency, the start of the EU unitary patent, and more.

BioPharmaceutical Europe

Deals Of The Week: Eisai Shares Full Compound Library In Screening Partnership With JHU

Academic drug-discovery collaborations with industry usually are limited by restraints companies place on how much of their compound libraries they’ll share in a collaboration. Plus the week’s top deals, including M&A transactions between Teva and NuPathe, and Par Pharmaceuticals and JHP.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Distributors
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Gehe AG
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Celesio AG
  • Senior Management
  • Fritz Oesterle, Chmn. & CEO
    Karl Gerhard-Elck, CFO
  • Contact Info
  • Celesio AG
    Phone: (49) 711 5001 00
    Neckartalstrasse 155
    Stuttgart , D-70376
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register